title: [Mitomycin-vinorelbine combination as second-line chemotherapy in metastatic cancer of the breast].
abstract: Fourty-six patients (41 evaluable) were treated in second line chemotherapy of metastatic breast cancer (MBC) by an association of mitomycin (M), vinorelbine (V) (M 8 mg/m2 D1, V 25 mg/m2 D1 and DI 8 every 4 weeks). Median age was 58 years (36-78), median performance status 1 (0-3). Thirty-seven per cent of the tumors were estrogen receptors positive and 17% progesterone receptors positive. Seventeen patients received an adjuvant chemotherapy and 39 a first line chemotherapy with anthracycline (A). The median number of metastatic sites was 2 (1-4) and 27 patients (67%) had visceral metastases. Twelve patients were refractory to anthracyclines and 5 resistant. No toxic death nor hemolytic uremic syndrome were observed. Seven (3.7%) febrile neutropenias happened responsible for 4 hospitalizations. A grade 3 or 4 neutropenia was noted in 34% of the cycles but no other clinic toxicity nor grade 3 or 4 thrombopenia. The rate of objective response (OR) was 37.5% with 2 complete responses (CR) and 13 partial responses (PR). Seven patients had stable disease and 18 progressed. The rate of hepatic OR was 31%. Five (40%) A-refractory patients responded but no resistant patient. Median OR time was 10 weeks (8-12) and median OR duration was 5 months (3-6). Median survival was 11.5 months. MV association is well tolerated and effective in second line chemotherapy for MBC even with hepatic metastasis and in patients refractory to anthracyclines.
authors.affiliation: Centre René-Huguenin, Saint-Cloud.
authors.forename: H
authors.initials: H
authors.lastname: Bourgeois
authors.forename: F
authors.initials: F
authors.lastname: Turpin
authors.forename: M
authors.initials: M
authors.lastname: Bouchada
authors.forename: A
authors.initials: A
authors.lastname: Volters
authors.forename: F
authors.initials: F
authors.lastname: Cvitkovic
authors.forename: A
authors.initials: A
authors.lastname: Goupil
authors.forename: M
authors.initials: M
authors.lastname: Janvier
authors.forename: M
authors.initials: M
authors.lastname: Tubiana-Hulin
authors.forename: P
authors.initials: P
authors.lastname: Soulie
authors.forename: J
authors.initials: J
authors.lastname: Berlie
authors.forename: M
authors.initials: M
authors.lastname: Girard
authors.forename: J
authors.initials: J
authors.lastname: Rouëssé
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D016685:Mitomycin; D014747:Vinblastine; D000077235:Vinorelbine
vernacular_title: Association mitomycine-vinorelbine en deuxième ligne chimiothérapique dans le cancer du sein métastatique.